ADMA BIOLOGICS, INC. (ADMA) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.2M sold). Latest close $13.56 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 16, 2026 · Congress to Nov 16, 2026.
Rubric Capital Management · Fundsmith · Perceptive Advisors — 3 tracked funds hold ADMA. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 5 sales ($2.2M). Insider trading
AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Rubric Capital Management | 0.72% | 9,339,414 | ADDED (+416.2%) Q3 filed Nov 16 |
| Fundsmith | 0.10% | 1,649,493 | HELD Q3 filed Nov 16 |
| Perceptive Advisors | 0.01% | 113,765 | TRIMMED (-75.7%) Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +58.3% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 323 of 8,857 filers |
| Long-only filers among them | 321 |
| Change vs 2026 Q1 | -27 net · 309 entered · 336 exited |
| Shares reported, all filers | 203,233,422 |
| Reported value, all filers | $1.7B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) (SIC 2836) |
| Revenue · FY2025 | $510.2M |
| Net income · FY2025 | $146.9M |
| Total assets · FY2025 | $624.2M |
| Shares outstanding | 223,984,680 |
| Market cap (at latest close) | $3.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Oct 15, 2026 | 19,528,063 |
| Share of shares outstanding | 8.72% |
| Days to cover | 6.55 |
Shares short at recent settlements — Jul 31, 2026: 21.9M · Aug 14, 2026: 22.7M · Aug 31, 2026: 23.9M · Sep 15, 2026: 24.2M · Sep 30, 2026: 20.6M · Oct 15, 2026: 19.5M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Oct 14, 2026 | 3,423 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 3K.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 5 sales by 2 insiders ($2.2M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Guiheen Lawrence P. | Sell | 10,000 | $13.92 | $139.2K | SEC filing | |
| Nov 16, 2026 | Grossman Adam S | President and CEO | Sell | 15,000 | $13.72 | $205.8K | SEC filing |
| Nov 16, 2026 | Grossman Adam S | President and CEO | Sell | 6,000 | $13.72 | $82.3K | SEC filing |
| Nov 5, 2026 | Grossman Adam S | President and CEO | Sell | 105,000 | $12.00 | $1.3M | SEC filing |
| Nov 5, 2026 | Grossman Adam S | President and CEO | Sell | 42,000 | $12.00 | $504.0K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | Tade Brad L. | Former Officer | 50,026 | $790.9K | Mar 10, 2026 | SEC filing |
| Mar 9, 2026 | Kestenberg-Messina Kaitlin M. | Officer | 10,096 | $155.4K | Mar 9, 2026 | SEC filing |
| Feb 17, 2026 | Grossman Adam S. | Director, Officer | 84,000 | $1.4M | Feb 17, 2026 | SEC filing |
| Oct 24, 2025 | Grossman Adam S. | Director and Officer | 63,000 | $960.8K | Oct 24, 2025 | SEC filing |
| Jul 15, 2025 | Grossman Adam S | Director and Officer | 63,000 | $1.2M | Jul 15, 2025 | SEC filing |
| Jun 12, 2025 | ELMS STEVE | Director | 425,621 | $9.3M | Jun 12, 2025 | SEC filing |
| Jun 9, 2025 | Grossman Jerrold B | Director | 10,000 | $206.1K | Jun 9, 2025 | SEC filing |
| Jun 4, 2025 | Lawrence P Guiheen Rev Tr DTD 09/20/19 | Director | 20,000 | $415.0K | Jun 4, 2025 | SEC filing |
| May 21, 2025 | Guiheen Lawrence P. | Director | 9,000 | $184.0K | May 21, 2025 | SEC filing |
| Mar 19, 2025 | Grossman Adam S | Director and Officer | 84,000 | $1.6M | Mar 19, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | STATE STREET CORPORATION | SC 13G | 17,116,022 | 7.4% | Jun 30, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 12,110,153 | 5.1% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 12, 2026 | Invesco Ltd. | SC 13G/A | 11,785,202 | 5.0% | Dec 31, 2025 | SEC filing |
| Aug 11, 2025 | STATE STREET CORPORATION | SC 13G | 12,078,505 | 5.1% | Jun 30, 2025 | SEC filing |
| Jul 29, 2025 | The Vanguard Group | SC 13G/A | 21,363,715 | 8.9% | Jun 30, 2025 | SEC filing |
| May 13, 2025 | STATE STREET CORPORATION | SC 13G | 11,440,778 | 4.8% | Mar 31, 2025 | SEC filing |
| May 9, 2025 | Invesco Ltd. | SC 13G | 12,866,904 | 5.4% | Mar 31, 2025 | SEC filing |
| Apr 30, 2025 | BlackRock, Inc. | SC 13G/A | 35,907,601 | 15.1% | Mar 31, 2025 | SEC filing |
| Feb 7, 2025 | Invesco Ltd. | SC 13G/A | 11,296,255 | 4.8% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 26 Lobbying Disclosure Act filings named this company as client, 2020–2026; most common issues: Defense (14), Health Issues (9).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Greenblatt Magic Formula — High earnings yield and high return on capital together
· Gross Profitability (Novy-Marx) — High gross profit relative to total assets
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Earnings Manipulation Suspect (Beneish) — Beneish M-Score above -1.78
· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)
· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)
Key figures
· Growth — Latest revenue: $510.2M · 5-yr revenue CAGR: 64.6% · Straight growth years: 7
· Greenblatt Magic Formula — Earnings yield: 6.5% · Return on capital: 41.4% · Combined rank: 73
· Gross Profitability (Novy-Marx) — Gross profit / assets: 46.9% · Gross margin: 57.4%
· Earnings Manipulation Suspect (Beneish) — M-Score: -0.18 · Receivables index: 2.65 · Margin deterioration: 0.90 · Sales growth index: 1.20 · Accruals ratio: 15.5%
· Auditor Change (8-K 4.01) — Latest event: Oct 31, 2024 · Events in 2 yrs: 2
· Late Filings (NT) — Latest event: Mar 3, 2025 · Events in 2 yrs: 1 · Latest form: NT 10-K
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2023 Q3, ranked #37 of 50.
Also held by the tracked funds that hold ADMA — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 5, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jun 2, 2026 | 5.07 Submission of Matters to a Vote of Security Holders | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on ADMA
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.